Posted by Michael Wonder on 27 Jun 2022
Trastuzumab deruxtecan supplemental new drug application submitted in Japan for patients with HER2 low metastatic breast cancer
27 June 2022 - Submission based on DESTINY-Breast04 results that showed trastuzumab deruxtecan demonstrated superior progression-free survival and overall survival versus chemotherapy
Daiichi Sankyo today announced that it has submitted a supplemental new drug application to Japan’s MHLW for trastuzumab deruxtecan for the treatment of adult patients in Japan with HER2 low unresectable or recurrent breast cancer after prior chemotherapy.
